Diagnosis and management of Castleman disease

Cancer Control

Volumn 21, Issue 4, 2014, Pages 266-278

  Soumerai, Jacob D ^a,b   Sohani, Aliyah R ^b   Abramson, Jeremy S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; C REACTIVE PROTEIN; CHLORAMBUCIL; CIDOFOVIR; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FIBRINOGEN; GANCICLOVIR; GLUCOCORTICOID; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; LENALIDOMIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PREDNISONE; RITUXIMAB; SILTUXIMAB; TOCILIZUMAB; VALGANCICLOVIR; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FOLLICULAR DENDRITIC CELL SARCOMA; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOALBUMINEMIA; IMMUNOHISTOCHEMISTRY; INCIDENCE; JUVENILE RHEUMATOID ARTHRITIS; KAPOSI SARCOMA; LYMPH NODE BIOPSY; MONOTHERAPY; MULTICENTRIC CASTLEMAN DISEASE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PARANEOPLASTIC PEMPHIGUS; PATHOGENESIS; POEMS SYNDROME; PROGRESSION FREE SURVIVAL; REMISSION; RHEUMATOID ARTHRITIS; STAGING; UNICENTRIC CASTLEMAN DISEASE; GIANT LYMPH NODE HYPERPLASIA;

GIANT LYMPH NODE HYPERPLASIA; HUMANS;

EID: 84907816443     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481402100403     Document Type: Article

References (102)

1. Castleman B, Towne V. CASE records of the Massachusetts General Hospital weekly clinicopathological exercises: case 40011. N Engl J Med. 1954;250(1):26-30.
2. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956;9(4):822-830.
3. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670-683.
4. Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128(8):657-662.
5. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman’s disease with oral etoposide. Am J Hematol. 2001;66(2):148-150.
6. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99(7):2331-2336.
7. B élec L, Mohamed AS, Authier FJ, et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman’s disease. Blood. 1999;93(11):3643-3653.
8. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266(5192):1865-1869.
9. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86(4):1276-1280.
10. An J, Lichtenstein AK, Brent G, et al. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood. 2002;99(2):649-654.
11. Keller SA, Hernandez-Hopkins D, Vider J, et al. NF-kappaB is essential for the progression of KSHV-and EBV-infected lymphomas in vivo. Blood. 2006;107(8):3295-3302.
12. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2013;122(26):4189-4198.
13. Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood. 2011;118(2):271-275.
14. Newsom-Davis T, Bower M, Wildfire A, et al. Resolution of AIDS-related Castleman’s disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma. 2004;45(9):1939-1941.
15. Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood. 2009;113(19):4521-4524.
16. Carbone A, De Paoli P, Gloghini A, et al. KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. Int J Cancer. 2014. [Epub ahead of print].
17. Ferry J, Harris N. Atlas of Lymphoid Hyperplasia and Lymphoma. Philadelphia: WB Saunders; 1997.
18. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406-1412.
19. Isaacson P, Campo E, Harris N. Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease. In: Swerlow S, Campo E, Harris N, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:258.
20. Chan JK. Newly available antibodies with practical applications in surgical pathology. Int J Surg Pathol. 2013;21(6):553-572.
21. Sato Y, Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman’s disease. Mod Pathol. 2009;22(4):589-599.
22. Cheuk W, Chan JK. Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity. Semin Diagn Pathol. 2012;29(4): 226-234.
23. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg. 2012;255(4):677-684.
24. Pietra G. Castleman’s angio-plasma-cellular lymph-node hyperplasia in roentgenograms [in German]. Fortschr Geb Rontgenstr Nuklearmed. 1964;101:665-667.
25. Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92(3):670-676.
26. de Vries IA, van Acht MM, Demeyere T, et al. Neoadjuvant radiotherapy of primary irresectable unicentric Castleman’s disease: a case report and review of the literature. Radiat Oncol. 2010;5:7.
27. Li YM, Liu PH, Zhang YH, et al. Radiotherapy of unicentric mediastinal Castleman’s disease. Chin J Cancer. 2011;30(5):351-356.
28. Matthiesen C, Ramgopol R, Seavey J, et al. Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature. Radiol Oncol. 2012;46(3):265-270.
29. Miranda FA, Faria VH, Arruda GV, et al. Radiation therapy in the treatment of unicentric Castleman’s disease. J Bras Pneumol. 2013;39(1):116-118.
30. Neuhof D, Debus J. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol. 2006;45(8):1126-1131.
31. Noh OK, Lee SW, Lee JW, et al. Cases report of unicentric Castleman’s disease: revisit of radiotherapy role. Radiat Oncol J. 2013;31(1):48-54.
32. Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3(9): 1202-1216.
33. Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10(1):25-35.
34. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman’s disease. J Clin Oncol. 2011;29(18):2481-2486.
35. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010;116(22):4415-4421.
36. Zietz C, Bogner JR, Goebel FD, et al. An unusual cluster of cases of Castleman’s disease during highly active antiretroviral therapy for AIDS. N Engl J Med. 1999;340(24):1923-1924.
37. Summerfield GP, Taylor W, Bellingham AJ, et al. Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids. J Clin Pathol. 1983;36(9):1005-1011.
38. Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol. 1985;16(2):162-172.
39. Stanley MW, Frizzera G, Dehner LP. Castleman’s disease, plasma-cell type. Diagnosis of central nervous system involvement by cerebrospinal fluid cytology. Acta Cytol. 1986;30(5):481-486.
40. Donaghy M, Hall P, Gawler J, et al. Peripheral neuropathy associated with Castleman’s disease. J Neurol Sci. 1989;89(2-3):253-267.
41. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer. 1999;85(3):706-717.
42. Park JB, Hwang JH, Kim H, et al. Castleman disease presenting with jaundice: a case with the multicentric hyaline vascular variant. Korean J Intern Med. 2007;22(2):113-117.
43. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10(1):61-67.
44. Colleoni GW, Duarte LC, Kerbauy FR, et al. 2-chloro-deoxyadenosine induces durable complete remission in Castleman’s disease but may accelerate its transformation to non-hodgkin’s lymphoma. Acta Oncol. 2003;42(7):784-787.
45. Bordeleau L, Bredeson C, Markman S. 2-chloro-deoxyadenosine therapy for giant lymph node hyperplasia. Br J Haematol. 1995;91(3):668-670.
46. Loi S, Goldstein D, Clezy K, et al. Castleman’s disease and HIV infection in Australia. HIV Med. 2004;5(3):157-162.
47. Uldrick TS, Polizzotto MN, O’Mahony D, et al. Rituximab combined with liposomal doxorubicin (R-Dox) in HIV-infected patients with severe Kaposi sarcoma-associated herpes virus (KSHV) associated multicentric Castleman disease (MCD). Infect Agent Cancer. 2010;5(suppl 1):A72.
48. Seo HY, Kim EB, Kim JW, et al. Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. Cancer Res Treat. 2009;41(2):104-107.
49. Lee JH, Kwon KA, Lee S, et al. Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. Leuk Res. 2010;34(1):e42-e45.
50. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB trial. J Clin Oncol. 2007;25(22):3350-3356.
51. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147(12):836-839.
52. Hoffmann C, Schmid H, Muller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118(13):3499-3503.
53. Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102(8):2786-2788.
54. Marrache F, Larroche C, Memain N, et al. Prolonged remission of HIV-associated multicentric castelman’s disease with an anti-CD20 monoclonal antibody as primary therapy. AIDS. 2003;17(9):1409-1410.
55. Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood. 2007;110(12):4132-4133.
56. Cervera Grau JM, Galiana Esquerdo G, Llorca Ferrandiz C, et al. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman’s disease induced with anti-CD20. Clin Transl Oncol. 2006;8(7):540-541.
57. Nicoli P, Familiari U, Bosa M, et al. HHV8-positive, HIV-negative multicentric Castleman’s disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol. 2009;90(3):392-396.
58. Law AB, Ryan G, Lade S, et al. Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int J Hematol. 2010;91(2):347-349.
59. Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman’s disease using rituximab. Eur J Haematol. 2006;76(2):119-123.
60. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013;19(13):3659-3670.
61. Casper C, Voorhees PM, Fayad LE, et al. An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman’s disease. Blood. 2013;122(21):1806-1806.
62. Casper C, Munshi N, Ke X, et al. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease. Blood. 2013;122(21):505-505.
63. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627-2632.
64. Muzes G, Sipos F, Csomor J, et al. Successful tocilizumab treatment in a patient with human herpesvirus 8-positive and human immunodeficiency virus-negative multicentric Castleman’s disease of plasma cell type nonresponsive to rituximab-CVP therapy. APMIS. 2013;121(7):668-674.
65. Nagao A, Nakazawa S, Hanabusa H. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases. J Hematol Oncol. 2014;7(1): 7-10.
66. Bottieau E, Colebunders R, Schroyens W, et al. Multicentric Castleman’s disease in 2 patients with HIV infection, unresponsive to antiviral therapy. Acta Clin Belg. 2000;55(2):97-101.
67. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977-6986.
68. Senanayake S, Kelly J, Lloyd A, et al. Multicentric Castleman’s disease treated with antivirals and immunosuppressants. J Med Virol. 2003;71(3): 399-403.
69. Schulte KM, Talat N. Castleman’s disease--a two compartment model of HHV8 infection. Nat Rev Clin Oncol. 2010;7(9):533-543.
70. Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103(5):1632-1634.
71. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood. 2004;103(11):4368-4369.
72. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3): 630-639.
73. Hess G, Wagner V, Kreft A, et al. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol. 2006;134(5):544-545.
74. Khan AA, Siraj F, Bhargava M, et al. Successful treatment of multicentric Castleman’s disease accompanying myeloma with bortezomib. BMJ Case Rep. 2012;2012: 10.1136/bcr-2012-007646.
75. Sobas MA, Alonso Vence N, Diaz Arias J, et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol. 2010;89(2):217-219.
76. Yuan ZG, Dun XY, Li YH, et al. Treatment of multicentric Castleman’s disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol. 2009;2:2-19.
77. Casquero A, Barroso A, Fernandez Guerrero ML, et al. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol. 2006;85(3):185-187.
78. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98(12): 3473-3475.
79. Turcotte LM, Correll CK, Reed RC, et al. Sustained remission of severe multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr Blood Cancer. 2014;61(4):737-739.
80. Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116(18):3627-3634.
81. Peterson BA, Frizzera G. Multicentric Castleman’s disease. Semin Oncol. 1993;20(6):636-647.
82. Larroche C, Cacoub P, Soulier J, et al. Castleman’s disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002;69(2):119-126.
83. Kessler E. Multicentric giant lymph node hyperplasia. A report of seven cases. Cancer. 1985;56(10):2446-2451.
84. Abdel-Reheim FA, Koss W, Rappaport ES, et al. Coexistence of Hodgkin’s disease and giant lymph node hyperplasia of the plasma-cell type (Castleman’s disease). Arch Pathol Lab Med. 1996;120(1):91-96.
85. Drut R, Larregina A. Angiofollicular lymph node transformation in Hodgkin’s lymphoma. Pediatr Pathol. 1991;11(6):903-908.
86. McAloon EJ. Hodgkin’s disease in a patient with Castleman’s disease. N Engl J Med. 1985;313(12):758.
87. Saletti P, Ghielmini M, Scali G, et al. Hodgkin’s and Castleman’s disease in a patient with systemic mastocytosis. Ann Hematol. 1999;78(2):97-100.
88. Zarate-Osorno A, Medeiros LJ, Danon AD, et al. Hodgkin’s disease with coexistent Castleman-like histologic features. A report of three cases. Arch Pathol Lab Med. 1994;118(3):270-274.
89. Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman’s disease. Am J Pathol. 1997;151(6):1517-1522.
90. Andhavarapu S, Jiang L. POEMS syndrome and Castleman disease. Blood. 2013;122(2):159.
91. Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(7):591-601.
92. B élec L, Authier FJ, Mohamed AS, et al. Antibodies to human herpesvirus 8 in POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome with multicentric Castleman’s disease. Clin Infect Dis. 1999;28(3):678-679.
93. Andriko JW, Kaldjian EP, Tsokos M, et al. Reticulum cell neoplasms of lymph nodes: a clinicopathologic study of 11 cases with recognition of a new subtype derived from fibroblastic reticular cells. Am J Surg Pathol. 1998;22(9):1048-1058.
94. Chan AC, Chan KW, Chan JK, et al. Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies. Histopathology. 2001;38(6): 510-518.
95. Chan JK, Fletcher CD, Nayler SJ, et al. Follicular dendritic cell sarcoma. clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized. Cancer. 1997;79(2):294-313.
96. Chan JK, Tsang WY, Ng CS. Follicular dendritic cell tumor and vascular neoplasm complicating hyaline-vascular Castleman’s disease. Am J Surg Pathol. 1994;18(5):517-525.
97. Fornelli A, Mureden A, Eusebi V. Follicular dendritic cell tumor and unusual vascular lesion in lymph node with Castleman’s disease. Description of a case. Pathologica. 1998;90(2):146-151.
98. Katano H, Kaneko K, Shimizu S, et al. Follicular dendritic cell sarcoma complicated by hyaline-vascular type Castleman’s disease in a schizophrenic patient. Pathol Int. 1997;47(10):703-706.
99. Lee IJ, Kim SC, Kim HS, et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman’s tumor. J Am Acad Dermatol. 1999;40(2 Pt 2):294-297.
100. Lin O, Frizzera G. Angiomyoid and follicular dendritic cell proliferative lesions in Castleman’s disease of hyaline-vascular type: a study of 10 cases. Am J Surg Pathol. 1997;21(11):1295-1306.
101. Kaplan I, Hodak E, Ackerman L, et al. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40(6):553-562.
102. Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol. 2009;48(2):162-169.